LEGGE, FRANCESCO

LEGGE, FRANCESCO  

Dipartimento di Medicina e Chirurgia  

Mostra records
Risultati 1 - 20 di 121 (tempo di esecuzione: 0.007 secondi).
Titolo Data di pubblicazione Autore(i) File
[Biological factors with prognostic significance in ovarian cancer]. Fattori biologici con significato prognostico nel cancro ovarico 1-gen-2001 Ferrandina, G; Legge, F; Fagotti, A; Fanfani, F; Mancuso, S; Scambia, G
[Familial ovarian carcinoma] 1-gen-2001 Greggi, S; Legge, F; Mancuso, S
A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge 1-gen-2007 Ferrandina, G; Legge, F; Mey, V; Nannizzi, S; Ricciardi, S; Petrillo, M; Corrado, G; Scambia, G
A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients 1-gen-2022 Loizzi, V; Cicinelli, E; Del Vecchio, V; Arezzo, F; Deromemaj, X; Kardhashi, A; Paradiso, A; Legge, F; Natalicchio, Mi; Resta, L; Resta, N; Loconte, Dc; Cormio, G
Adjuvant volumetric-modulated arc therapy with simultaneous integrated boost in endometrial cancer. Planning and toxicity comparison 1-gen-2014 Macchia, G; Cilla, S; Morganti, Ag; Deodato, F; Legge, F; Piermattei, A; Chiantera, V; Scambia, G; Valentini, V; Ferrandina, G
Advances in surgical management of cervical cancer 1-gen-2009 Ercoli, A; Iannone, V; Legge, F; Fagotti, A; Fanfani, F; Carone, V; D'Asta, M; Scambia, G; Ferrandina, G
Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinicopathological parameters 1-gen-2004 Fagotti, A; Ferrandina, G; Fanfani, F; Legge, F; Lauriola, L; Gessi, M; Castelli, P; Barbieri, F; Minelli, L; Scambia, G
Analysis of survivin expression in ovarian cancer and its correlation with clinical, surgical, pathological and apoptosis-related parameters 1-gen-2004 Ferrandina, G; Legge, F; Martinelli, E; Gessi, M; Gallotta, V; Salutari, V; Zannoni, Gf; Ranelletti, Fo; Scambia, G
Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study 1-gen-2022 Restaino, S; Buda, A; Puppo, A; Capozzi, Va; Sozzi, G; Casarin, J; Gallitelli, V; Murgia, F; Vizzielli, G; Baroni, A; Corrado, G; Pasciuto, T; Ferrari, D; Novelli, A; Berretta, R; Legge, F; Vizza, E; Chiantera, V; Ghezzi, F; Landoni, F; Scambia, G; Fanfani, F
Angiogenesis inhibitors in gynecological cancers 1-gen-2003 Ferrandina, G; Legge, F; Gallotta, V; Salutari, V; Scambia, G
Biologia e genetica molecolare in ginecologia ed ostetricia 1-gen-2013 Legge, F; Ferrandina, G; Paglia, A; Scambia, G; Legge, F; Ferrandina, G; Paglia, A; Scambia, G
Biologia e genetica molecolare in ginecologia ed ostetricia 1-gen-2007 Legge, F; Ferrandina, G; Paglia, A; Scambia, G
Biological characterization of ovarian cancer: prognostic and therapeutic implications 1-gen-2005 Legge, F; Ferrandina, G; Salutari, V; Scambia, G
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease 1-gen-2002 Ceccaroni, M; Genuardi, M; Legge, F; Lucci-Cordisco, E; Carrara, S; D'Amico, F; Greggi, S; Scambia, G
Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III 1-gen-2011 Pignata, S; Scambia, G; Ferrandina, G; Savarese, A; Sorio, R; Breda, F; Gebbia, V; Musso, P; Frigerio, L; Del Medico, P; Lombardi, Av; Febbraio, A; Scollo, P; Ferro, A; Tamberi, S; Brandes, A; Ravaioli, A; Valerio, Mr; Aitini, E; Natale, D; Scaltriti, L; Greggi, S; Pisano, C; Lorusso, D; Salutari, V; Legge, F; Di Maio, M; Morabito, A; Gallo, C; Perrone, F
Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial 1-gen-2010 Pignata, S; Scambia, G; Savarese, A; Sorio, R; Breda, E; Legge, F; Gebbia, V; Musso, P; Gallo, C; Perrone, F on behalf of MITO group
Celecoxib modulates angiogenesis-related parameters in both sera and tumor biopsies from cervical cancer patients 1-gen-2005 Legge, F; Ranelletti, Fo; Zannoni, Gf; Martinelli, E; Gessi, M; Salutari, V; Gallotta, V; Lorusso, D; Scambia, G; Ferrandina, G
Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: A pilot study 1-gen-2003 Ferrandina, G; Ranelletti, Fo; Legge, F; Lauriola, L; Salutari, V; Gessi, M; Testa, Ac; Werner, U; Navarra, P; Tringali, G; Battaglia, A; Scambia, G
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study 1-gen-2003 Ferrandina, G; Ranelletti, Fo; Legge, F; Lauriola, L; Salutari, V; Gessi, M; Testa, Ac; Werner, U; Navarra, P; Tringali, G; Battaglia, A; Pozzo, C; Scambia, G
Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a phase II study 1-gen-2005 Ferrandina, G; Legge, F; Gallotta, V; Lorusso, D; Testa, Ac; Salutari, V; Paglia, A; Col angelo, M; Fulfaro, F; Scambia, G